i-Pharm GxP’s Post

In the ever-evolving landscape of #healthcare innovation, the potential impact of #GenerativeAI cannot be ignored. Quantic alum, Dr. Jumaah I. Goldberg, DPT, VP of Medical and Regulatory Affairs at a cutting-edge AI diagnostics startup, offers insights on AI's potential in the pharmaceutical industry. What are your thoughts on the future of #AI in healthcare? Across all industries, what challenges and opportunities are you seeing for business leaders in integrating new technologies to drive value? #Innovation #MedTech #BusinessStrategy #FutureOfBusiness

Opyl is proud to partner with Commercial Eyes Pty Ltd, a respected consultancy in life sciences, to support their clients with AI-powered market research and competitive intelligence, using the TrialKey platform. As part of ProductLife Group, Commercial Eyes brings a global network and deep expertise in pharmaceutical and medtech commercialisation. Together, we’ll empower their clients with strategic insights and data-driven solutions, improving the success of clinical trials and market positioning. Tanya van der Wall, Country Managing Director at Commercial Eyes commented: “We are excited to collaborate with Opyl and leverage their advanced AI capabilities to enhance the innovative data driven insights we provide to our clients. This partnership also aligns with our global AI strategy to co-create innovative AI enabled solutions with our own dedicated best in class expertise and tools and the right partners. The insights gained through Opyl's platform will enhance our ability to guide our clients through complex market landscapes and position them for success and most importantly, to enable better and faster access for patients to life saving and life changing therapies” Book a TrialKey demo:https://appt.link/minhthu Marketing & Investor Enquiries: bernice@trialkey.ai #marketresearch #biotech #pharmaceuticals #pharma #medtech #lifesciences #clinicaltrials #medicaldevices

Join us for the upcoming webinar "Generative AI: Transforming Drug Development in Life Sciences" on May 7th at 10am ET! As part of our Analytics in 20 series, this session will explore how #GenAI is revolutionizing pharmaceutical development and shaping the future of the industry. 

Interesting short analysis in Nature Reviews Drug Discovery early publishing by Alexander Roland and Ann Baker. My favourite theme: decision making. Or as they reason to understand the large variation in R&D efficiency in the cohort they analysed: „If a given company’s R&D efficiency problem is primarily driven by low late-stage success rates, for example, several root causes might be considered. Have low-quality projects been progressing owing to poor decision-making around success criteria in early-stage research, effectively delaying attrition to later stages? Or could problems be due to portfolio rationalization following a major merger, or perhaps a short-term impact of therapeutic area refocusing? Real-world precedents exist for these scenarios and more.“ Speaking from my own experience, companies are still taking shortcuts and leave out too much important data, which in turn makes data driven decisions difficult (as the data is not there). Question based approaches assure you can carefully consider your assets. Does it translate? What part of the clinical data? Are the (animal) models merely revealing target validity? Can we meassure biological effects? Biomarkers in place? Validated? We seem very molecular driven until we enter the clinical domain…

Attention: Life Science Trailblazers! "AI-enabled digital transformation is fast becoming a strategic imperative for leaders in life sciences. The biopharma industry is on the brink of large-scale disruption driven by interoperable data, advances in AI and analytics, open and secure platforms and patient-centric care, which have the potential to deliver less costly and more productive drug development. When developing the business case for investment in digital and AI, the short-term costs need to be balanced against the longterm efficiency gains. Executing large-scale strategies requires setting up a governance function for making investments, assessing value realised, and monitoring ethical and legal risks from use of AI." (Deloitte; "Unleash AI’s potential Measuring the return from pharmaceutical innovation – 14th edition")

Are you aware of how technological advances are helping to shorten drug development and manufacturing timelines?   With automated workflows, real-time monitoring and the introduction of AI, drug development and manufacturing are being streamlined. These technological advances are helping to reduce timelines so vital medicines can be delivered to patients at speed.   Advances in technology are transforming analytical testing.   Find out more in the recent feature from Drug Development & Delivery, where our Vice President, Analytical Development, Dr. Ramesh Jagadeesan explores how analytical testing approaches are being transformed by technological advances.   Read more here: https://lnkd.in/dteTqYjC   #drugdevelopment #drugmanufacturing #CDMO

Imagine a new technology that could revolutionize clinical trials and the development of pharmaceutical products, one that could make it faster to safely bring patient treatments to market. The healthcare industry is on the cusp of transformation thanks to recent advances in AI. In this new paper by Keystone’s Mary Scarpulla, Aseem Mahajan, and Monika Pichler, in collaboration with Keystone expert Luba Greenwood, J.D. and Keystone alumna Colleen Carroll, we explore the technological advancements that have enabled the advent of advanced analytical tools in the healthcare space that paved the way for Digital Twin technology, and the nuances global regulators must navigate to facilitate adoption while ensuring patient safety. Click here to read more: https://bit.ly/4fvKPd3 #AI #DigitalTwins #HealthcareInnovation #DrugDevelopment #ClinicalTrials #Pharma #Technology #FutureOfMedicine

Have you heard about #GenAI? Kidding, of course you have! With advancements in technology and a growing demand for innovative solutions, the opportunities for transformative change are endless. Are you ready to embrace the future of healthcare and lead the way in shaping tomorrow's treatments? Let's explore the possibilities together with #lifesciences industry leaders in our upcoming Analytics in 20 webinar on GenAI: Transforming Drug Development in Life Sciences. Grab your spot today: https://lnkd.in/gNDi7KKH #PharmaceuticalInnovation #HealthcareTransformation #FutureOfMedicine

What’s driving pharma’s big jump in internal rate of return on R&D investments—4.1% in 2023 for the top-20 pharma companies, up from a dismal 1.2% a year earlier? Continuing investment in breakthrough science obviously plays a part, but that’s always been the case. There are early signs that the growing infusion of AI (both classical and generative) into the R&D process is having an impact—and not just in drug discovery but also in running more efficient clinical trials and then using trial data to make better-informed commercialization decisions.   Pharma faces real headwinds, but there are enough bright spots (like this one) for me to feel extremely optimistic.

Please join our CXO Roundtable in Bengaluru to learn practical GenAI solutions for Pharma Industry!